AKAnne Kerr

Anne Kerr

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Anne Kerr has a total of 30 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    1385 Virtual urgent care for children: a proof of concept trial

    by Bimal Mehta, Sarah Fissler, Ian Gilbertson, Dani Jones, Anne Kerr, Rayyan Nasser, Carol Platt, Matt Rotheram

    Background Telemedicine is increasingly used internationally to provide clinical services when patient and clinician are not in the same room. In anticipation of limited physical capacity to meet patient activity within our Paediatric Emergency Department (PED) during the Covid-19 pandemic, we developed a video-consultation urgent care model. We describe the process developed, results and lessons learned from a proof of concept trial. Objectives As an innovative model for the UK we sought to test feasibility, safety and acceptability for clinicians, patients and carers at a type 1 PED. Methods Our model was developed by our clinical, IM&T and Innovation teams following workshops with colleagues delivering similar models internationally. The trial was conducted over 4 weeks on non-consecutive days based on the availability of trial clinicians who were senior PEM-trained clinicians. Patients who did not require immediate resuscitation based on our usual nurse eyeball assessment were invited to participate in a video-consultation trial. Carers who volunteered were registered on the hospital Patient Administration System (PAS) and received an automated text message link to join a video-consultation on NHS Attend Anywhere using their own device. The clinician was based remotely on a video-equipped laptop or desktop. The patient did not have any triage or physiological observations measured prior to video-consult. A range of outcomes was available to clinician and carer as described in the Results. Clinicians documented directly into the PAS. Clinician and patient-carer feedback was solicited at the end of consultations. Results 31 patients were seen. Age range 1 month – 15 years; 12 female: 19 male. Presenting complaints included rash, headache – both new and chronic, cough, sore throat, difficulty breathing, diarrhoea or vomiting, eye conditions, allergy, suspected UTI, musculoskeletal complaints and injuries. 25% (8 patients) were brought to ED for further action: 4 patients for x-ray or physical examination; 2 for urine dipstick and 2 to issue a prescription. 1 patient (3.2%) returned within 7 days with same problem with overnight admission for observation only. This is comparable to our usual re-attender rate. Clinical assessment and advice during video consult was reviewed and deemed appropriate. There were no other unplanned returns in the 2 weeks following initial attendance. Feedback suggests video-consultation is acceptable to carers, especially when waiting times are long. Conclusions 75% of patients were safely managed with verbal advice only. Of those that needed to attend the PED for investigation or prescription, local options could be implemented to reduce need to travel. Virtual urgent care is feasible, safe and acceptable for clinicians and carers of infants, children and young people. Based on the range of presenting complaints seen during the trial, a significant proportion of attendances to our type 1 PED could be effectively managed through this model.

  • Open Access

    Diagnostic layering: Patient accounts of breast cancer classification in the molecular era

    by Emily Ross, Julia Swallow, Anne Kerr, Choon Key Chekar, Sarah Cunningham-Burley


  • Open Access

    Going private

    by Anne Kerr, Choon Key Chekar, Emily Ross, Julia Swallow, Sarah Cunningham-Burley

    While many cancer patients experience molecular diagnostics and targeted therapies as part of standard treatment or through clinical trials provided free-of-charge through the NHS, others turn to private providers to craft their own care pathways, utilising private health insurance, savings, taking out loans or raising money via crowdfunding online. In Chapter 6, we explore how practitioners, patients and their relatives seek to tailor their care and treatment pathways via these kinds of engagements with private healthcare. We examine ambivalence about access to expensive experimental treatments as part of NHS or private care, and draw associations between optimisation, actionability and adaptability via personalised diagnosis and therapies and patient entrepreneurship, and the intensified responsibilities for health and healthcare therein. Through this exploration we situate personalisation in relation to transformations in citizenship and consumption via social media platforms, and argue that this brings another layer of care, biosociality and identity work for patients and their relatives as they navigate the hope and social obligations of personalised cancer therapies.

  • Open Access

    Contents

    by Anne Kerr, Choon Key Chekar, Emily Ross, Julia Swallow, Sarah Cunningham-Burley

    "Contents" published on 19 Jan 2021 by Manchester University Press.

  • Open Access

    Conclusion

    by Anne Kerr, Choon Key Chekar, Emily Ross, Julia Swallow, Sarah Cunningham-Burley

    "Conclusion" published on 19 Jan 2021 by Manchester University Press.

  • Open Access

    Introduction

    by Anne Kerr, Choon Key Chekar, Emily Ross, Julia Swallow, Sarah Cunningham-Burley

    In this chapter we introduce the topics, case studies and the main themes of the book, exploring the medical and scientific, political and economic backdrop to personalised cancer medicine as the context for our study. After briefly outlining our methodology, we describe our orientation to the subject, the key questions and academic influences we have drawn upon and introduce each of the chapters to follow.

  • Open Access

    Front matter

    by Anne Kerr, Choon Key Chekar, Emily Ross, Julia Swallow, Sarah Cunningham-Burley

    "Front matter" published on 19 Jan 2021 by Manchester University Press.

  • Open Access

    Bibliography

    by Anne Kerr, Choon Key Chekar, Emily Ross, Julia Swallow, Sarah Cunningham-Burley

    "Bibliography" published on 19 Jan 2021 by Manchester University Press.

  • Open Access

    Acknowledgements

    by Anne Kerr, Choon Key Chekar, Emily Ross, Julia Swallow, Sarah Cunningham-Burley

    "Acknowledgements" published on 19 Jan 2021 by Manchester University Press.

  • Open Access

    Polygenic risk-stratified screening for cancer: Responsibilization in public health genomics

    by Anne Kerr, Tineke Broer, Emily Ross, Sarah Cunningham Burley

    In this article, we examine professional discourse around the development of polygenic risk-stratified screening (PRSS) for cancer. Analyzing a range of contemporary professional literatures from Europe, North America and Australia, we explore how the drive to screen for molecular markers of cancer risk makes professionals, screening recipients and publics responsible, in different ways, for acquiring, curating and analyzing molecular data. Investigating how these responsibilities are invoked in discussions of new data practices, technologies, organizational arrangements, engagement, education and protocols for participation, we argue that agendas for PRSS for cancer are both expanding and stratifying responsibilities. Data collection is to be achieved by intensified responsibilities for including, reassuring and recruiting populations, as well as by opening and enriching the datasets on which models and preventative screening arrangements are based. Enhanced responsibilities for screening recipients and publics are also invoked, not just in relation to personal health but for population health more generally, via research participation and consenting to data re-use in the public interest. Professionals, screening recipients and publics are also to become responsible for moderating expectations of screening according to genomic designations. Together these discourses go beyond individual risk management to extend and diversify the responsibilities of practitioners, screening recipients and publics as public health genomics develops.